Inhibikase Therapeutics
IKT
IKT
104 hedge funds and large institutions have $193M invested in Inhibikase Therapeutics in 2026 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 38 increasing their positions, 14 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
54.35% less ownership
Funds ownership: 141.56% → 87.21% (-54%)
Holders
104
Holding in Top 10
3
Calls
–
Puts
–
Top Buyers
| 1 | +$5.32M | |
| 2 | +$4.9M | |
| 3 | +$3.68M | |
| 4 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$3.34M |
| 5 |
SC
SummitTX Capital
Fort Worth,
Texas
|
+$2.71M |
Top Sellers
| 1 | -$5.52M | |
| 2 | -$2.82M | |
| 3 | -$2.59M | |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.47M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.18M |
